SEENERGIE
Unleash Human Potential
Thymosin Alpha-1
Regulates cell functions to improve immune responses, reduce inflammation, and speed up wound healing.
Active ingredient:
28 amino acids
Molecular formula:
C129H215N33055
Molecular weight:
3108.3 g/mol
Intake:
Injection
Thymosin Alpha-1
Active ingredient:
28 amino acids
Molecular formula:
C129H215N33055
Molecular weight:
3108.3 g/mol
Intake:
Injection
What is
Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a small protein peptide consisting of 28 amino acids. It is a naturally occurring molecule found in the thymus gland, where it was first discovered, and is involved in regulating immune cell function.
Tα1 has been shown to have a variety of biological effects, including enhancing T-cell function, promoting the production of cytokines, and modulating the immune response. It has been found to stimulate the maturation of T-cells, which are important for immune system function, and to increase the production of interferon-gamma, a cytokine that activates immune cells and enhances immune function.
Research has also shown that Tα1 has potential therapeutic applications in a variety of medical conditions, including viral infections, cancer, and autoimmune diseases. It has been found to enhance the immune response to viral infections, such as hepatitis B and C, and to have antitumor effects by promoting apoptosis (programmed cell death) in cancer cells. Additionally, Tα1 has been shown to have anti-inflammatory effects and may help to reduce the symptoms of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
Benefits
- Suppress tumor growth
- Exhibit antiviral properties
- Exhibit antifungal properties
- Help eradicate unhealthy cells
- Exhibit antibacterial properties
- Increase vaccine effectiveness
- Stop infection or cancer growth
- Strengthen your immune system
- Enhance function of certain immune cells
- Improve symptoms of associated with chronic fatigue
Protocols
- Content and Potency
Provided as a 10mg lyophilized vial
- Suggested Dosage
- Initiation: Thymosin Alpha-1 therapy is initiated to enhance immune function, support infection control, and improve overall health.
- Initial Dose: Begin with 0.8 mg (0.16 ml or 16 units) subcutaneously twice weekly for the first two weeks to assess tolerance and minimize potential side effects.
- Titration: If well tolerated, increase the dose to 1.6 mg (0.32 ml or 32 units) subcutaneously twice weekly after the initial two-week period.
- Maintenance: Maintain the dose at 1.6 mg (0.32 ml or 32 units) subcutaneously twice weekly for ongoing support of immune function and overall health improvement.
- Duration: Thymosin Alpha-1 is administered twice weekly.
- Weeks 1-2: 0.8 mg (0.16 ml or 16 units) of Thymosin Alpha-1 twice weekly
- Week 3 and onwards: 1.6 mg (0.32 ml or 32 units) of Thymosin Alpha-1 twice weekly
*Provided as a standard protocol, dose may vary depending on the condition of the patient.
*The dosage of Thymosin Alpha-1 may be adjusted based on the individual’s response, medical history, and specific treatment goals.
- Restrictions
- Known hypersensitivity to Thymosin Alpha-1 or any component of the formulation.
- Not recommended for use during pregnancy or breastfeeding unless specifically advised by a healthcare provider.
- Caution in patients with autoimmune diseases, as the modulation of the immune system may exacerbate symptoms.
- Thymosin Alpha-1 should not be used in patients with severe hepatic or renal impairment without close medical supervision.
- Requirements
- Regular monitoring of immune function and overall health to assess the effectiveness of the treatment.
- Periodic blood tests to check for any adverse effects and to adjust the treatment as necessary.
- Consultation with a healthcare professional before starting Thymosin Alpha-1 to ensure it is appropriate for the patient’s health condition
Procedure
- Thymosin Alpha-1
Reconstitution
- Draw 2 ml of sterile water for injection into a syringe.
- Inject the sterile water into a vial containing 10 mg of Thymosin Alpha-1 peptide.
- Gently swirl the vial until the peptide is fully dissolved.
- Administration
- Remove the cap from a tuberculin syringe.
- Draw the reconstituted Thymosin Alpha-1 solution into the syringe to the required dosage (0.16 ml or 16 units initially, 0.32 ml or 32 units after titration).
- Clean the selected injection site with an alcohol swab.
- Pinch the sanitized skin and insert the needle at a 90-degree angle.
- Administer the injection subcutaneously.
- For next usage
- Store the remaining Thymosin Alpha-1 solution in the refrigerator at 2-8°C.
- Before the next use, clean the vial top with an alcohol swab.
- Use a new syringe for each administration.
- Ensure to rotate injection sites (abdomen, thigh, or upper arm) to minimize skin irritation).
Clinical Research
Study:
Thymosin Alpha-1 (Tα1) for Immune Modulation
Source:
Immunity & Ageing, Frontiers in Oncology, Inflammopharmacology
Results:
Thymosin Alpha-1 (Tα1) is a peptide with potent immunomodulatory properties, playing a critical role in enhancing the body’s immune response. It has been widely studied for its therapeutic potential in treating viral infections, including COVID-19, as well as in cancer therapy.
Tα1 modulates the immune system by stimulating the production and activity of T cells, dendritic cells, and cytokines. It enhances the body’s ability to respond to infections by promoting the maturation and differentiation of T cells, increasing the efficacy of the immune response. Tα1 interacts with Toll-like receptors, which are crucial for pathogen recognition and activation of innate immunity.
Numerous clinical trials have demonstrated the safety and efficacy of Tα1 in treating viral infections and cancer. For COVID-19, Tα1 has been used in combination with standard treatments to improve patient outcomes. In cancer therapy, Tα1 has been incorporated into treatment protocols to enhance immune response and improve the overall effectiveness of chemotherapy and immunotherapy.
Immunity & Ageing, 2020; Frontiers in Oncology, 2019; Inflammopharmacology, 2020.
Read More: https://immunityageing.biomedcentral.com/articles/10.1186/s12979-020-00202-1, https://www.frontiersin.org/articles/10.3389/fonc.2019.00873/full, https://link.springer.com/article/10.1007/s10787-020-00778-0
Articles
The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study
A total of 771 patients were included, and 327/771 (42.4%) patients received thymosin α1 therapy. The 28-day mortality in thymosin group was significantly lower than that in control group (41.3% vs. 60.6%, p < 0.001). After PSM 522 patients were included in analysis and the 28-day mortality in thymosin α1 group and control group were […]
A Reappraisal of Thymosin Alpha1 in Cancer Therapy
Thymosin alpha1 (Tα1), an endogenous peptide first isolated from the thymic tissue in the mid-sixties, has gained considerable attention for its immunostimulatory activity that led to its application to diverse pathological conditions, including cancer. Studies in animal models and human patients have shown promising results in different types of malignancies, especially when Tα1 was used […]
Doctor's Reviews
Thymosin Alpha 1
Thymosin Alpha 1 is an immune system support peptide. It is made up of 28 amino acid chains.
Thymosin Alpha 1 and the Immune System
Dr. Eric reviews Thymosin Alpha 1 and its role in the immune system. He also reviews other ways to support your body’s natural immune system function to fight viral, bacterial and fungal infections!
What you need to know about Peptide Thymosin Alpha | Peptide | Wellness Lounge
Thymosin alpha peptide is a naturally occurring protein that plays a crucial role in the functioning of the immune system. It is produced by the thymus gland, which is located in the chest area and is responsible for the development of T-cells, a type of white blood cell that helps the body fight off infections […]
